Nuveen, LLC Janux Therapeutics, Inc. Transaction History

Nuveen, LLC

$315 Billion
Q1 2025

A detailed history of Nuveen, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 123,679 shares of JANX stock, worth $2.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,679

Holding current value

$2.86 Million

% of portfolio

0.0%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 12, 2025	BUY	$27.0 - $57.81 $3.34 Million - $7.15 Million	123,679 New	123,679 $3.34 Million

Others Institutions Holding JANX

# of Institutions

193

Shares Held

57.3M

Call Options Held

626K

Put Options Held

155K

Ra Capital Management, L.P. Boston, MA

11.2M
Shares

$259 Million
6.27% of portfolio
Janus Henderson Group PLC London, X0

4.6M
Shares

$106 Million
0.07% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.65M
Shares

$84.6 Million
0.19% of portfolio
Paradigm Biocapital Advisors LP New York, NY

3.33M
Shares

$77.1 Million
4.61% of portfolio
Black Rock Inc. New York, NY

2.34M
Shares

$54.3 Million
0.0% of portfolio

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $964M
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen, LLC with notifications on news.

Account